3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Leukemia
7
Leukemia, Myeloid, Acute
6
Blast Crisis
6
Leukemia, Myeloid, Accelerated Phase
5
Carcinoma, Non-Small-Cell Lung
5
Leukemia, Myeloid, Chronic-Phase
4
Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Breast Neoplasms
2
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Piebaldism
1
Philadelphia Chromosome
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Malignant Hepatobiliary Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Interventions
Oxaliplatin
18
Surveys and Questionnaires
15
Fluorouracil
15
Capecitabine
13
Leucovorin
12
Blood Specimen Collection
11
Irinotecan
10
Standard of Care
7
Cisplatin
7
Endoscopic Mucosal Resection
6
atezolizumab
5
Specimen Handling
5
Radiotherapy
5
Educational Status
5
Drug Therapy
5
Docetaxel
5
S 1 (combination)
4
Radiosurgery
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Interviews as Topic
4
Gemcitabine
4
Everolimus
4
Colonoscopy
4
Biopsy
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
apatinib
3
Remote Patient Monitoring
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled